Fauci says leak concerns fueled his White House revelation of Gilead drug results
Excerpt: Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running the trial, said he took the first opportunity to get the word out that patients taking a dummy treatment or placebo should be switched to remdesivir in hopes of benefiting from it. He expressed concern that leaks of partial information would lead to confusion. (...) "It was purely driven by ethical concerns," Fauci told Reuters in a telephone interview. "I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have a situation where the ethical concern about getting the drug to people on placebo dominates the conversation." An independent data safety and monitoring board, which had looked at the preliminary results of the NIAID trial, determined it had met its primary goal of reducing hospital stays. [Another little bit of encouraging news, but note they’re being very conservative in claims of benefits from it. Ron P.]
Posts
No comments:
Post a Comment